Template:Antithrombotics: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Template:Antithrombotics" [edit=sysop:move=sysop]) |
No edit summary |
||
Line 1: | Line 1: | ||
{{Navbox | {{Navbox | ||
| name | | name = Antithrombotics | ||
| title = [[Antithrombotic]]s ([[ | | title = [[Antithrombotic]]s ([[Thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]]) | ||
| | | state = {{{state<includeonly>|autocollapse</includeonly>}}} | ||
| bodyclass = hlist | |||
| group1 = [[Antiplatelet drug]]s | | group1 = [[Antiplatelet drug]]s | ||
| | | list1 = {{Navbox|child | ||
| group1 = [[Glycoprotein IIb/IIIa inhibitors]] | | group1 = [[Glycoprotein IIb/IIIa inhibitors]] | ||
| | | list1 = | ||
* [[Abciximab]] | |||
* [[Eptifibatide]] | |||
* [[Orbofiban]] | |||
* [[Roxifiban]] | |||
* [[Sibrafiban]]<sup>§</sup> | |||
* [[Tirofiban]] | |||
| group2 = [[ADP receptor | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | ||
| | | list2 = | ||
* [[Thienopyridine]]s | |||
** [[Clopidogrel]] | |||
** [[Prasugrel]] | |||
** [[Ticlopidine]] | |||
* [[Nucleotide]]/[[nucleoside]] analogs | |||
** [[Cangrelor]] | |||
** [[Elinogrel]] | |||
** [[Ticagrelor]] | |||
| group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) | | group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) | ||
| | | list3 = | ||
* [[Beraprost]] | |||
* [[Iloprost]] | |||
* [[Prostacyclin]] | |||
* [[Treprostinil]] | |||
| group4 = [[Mechanism of action of aspirin|COX inhibitors]] | | group4 = [[Mechanism of action of aspirin|COX inhibitors]] | ||
| | | list4 = | ||
* [[Aspirin|Acetylsalicylic acid/Aspirin]]<sup>#</sup> | |||
* [[Aloxiprin]] | |||
* [[Carbasalate calcium]] | |||
* [[Indobufen]] | |||
* [[Triflusal]] | |||
| group5 = | | group5 = [[Thromboxane inhibitors]] | ||
| | | list5 = | ||
* [[Thromboxane synthase inhibitors]] | |||
** [[Dipyridamole]] ([[Acetylsalicylic acid/dipyridamole|+ aspirin]]) | |||
** [[Picotamide]] | |||
** [[Terbogrel]] | |||
* [[Thromboxane receptor antagonist|Receptor antagonist]]s | |||
** [[Terbogrel]] | |||
** [[Terutroban]]<sup>§</sup> | |||
| group6 = [[Phosphodiesterase inhibitor]]s | |||
| list6 = | |||
* [[Cilostazol]] | |||
* [[Dipyridamole]] | |||
* [[Triflusal]] | |||
| | | group7 = Other | ||
| list7 = | |||
* [[Cloricromen]] | |||
* [[Ditazole]] | |||
* [[Vorapaxar]] | |||
}} | |||
| group2 = [[Anticoagulant]]s | |||
| list2 = {{Navbox|child | |||
| evenodd = swap | |||
| group1 = [[Vitamin K antagonist]]s<br />(inhibit [[Thrombin|II]], [[Factor VII|VII]], [[Factor IX|IX]], [[Factor X|X]]) | |||
| list1 = | |||
* [[Coumarin]]s: [[Acenocoumarol]] | |||
* [[Coumatetralyl]] | |||
* [[Dicoumarol]] | |||
* [[Ethyl biscoumacetate]] | |||
* [[Phenprocoumon]] | |||
* [[Warfarin]]<sup>#</sup> | |||
* [[1,3-Indandione]]s: [[Clorindione]] | |||
* [[Diphenadione]] | |||
* [[Phenindione]] | |||
* Other: [[Tioclomarol]] | |||
| group2 = [[Factor Xa]] inhibitors< | | group2 = [[Factor Xa]] inhibitors<br />(with some II inhibition) | ||
| | | list2 = {{Navbox|child | ||
| group1 = [[Heparin]] group/< | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | ||
| list1 | | list1 = | ||
* [[Low molecular weight heparin]] | |||
** [[Bemiparin sodium|Bemiparin]] | |||
** [[Certoparin sodium|Certoparin]] | |||
** [[Dalteparin sodium|Dalteparin]] | |||
** [[Enoxaparin sodium|Enoxaparin]] | |||
** [[Nadroparin calcium|Nadroparin]] | |||
** [[Parnaparin sodium|Parnaparin]] | |||
** [[Reviparin sodium|Reviparin]] | |||
** [[Tinzaparin sodium|Tinzaparin]] | |||
* [[Oligosaccharide]]s | |||
** [[Fondaparinux]] | |||
** [[Idraparinux]]<sup>§</sup> | |||
* [[Heparinoid]]s | |||
** [[Danaparoid]] | |||
** [[Dermatan sulfate]] | |||
** [[Sulodexide]] | |||
| group2 = [[Direct Xa inhibitor]]s ("xabans") | |||
| list2 = | |||
* [[Apixaban]] | |||
* [[Betrixaban]] | |||
* [[Darexaban]]<sup>§</sup> | |||
* [[Edoxaban]] | |||
* [[Otamixaban]]<sup>§</sup> | |||
* [[Rivaroxaban]] | |||
}} | |||
<!-- group3 omitted to preserve alternating striping --> | |||
| group4 = [[Direct thrombin inhibitor|Direct thrombin (IIa) inhibitor]]s | |||
| list4 = | |||
* [[Direct thrombin inhibitor#Bivalent|Bivalent]]: [[Hirudin]] | |||
** [[Bivalirudin]] | |||
** [[Desirudin]] | |||
** [[Lepirudin]] | |||
* [[Direct thrombin inhibitor#Univalent|Univalent]]: [[Argatroban]] | |||
* [[Dabigatran]] | |||
* [[Efegatran]] | |||
* [[Inogatran]]<sup>§</sup> | |||
* [[Melagatran]]<sup>‡</sup> | |||
* [[Ximelagatran]]<sup>‡</sup> | |||
| | | group5 = Other | ||
| list5 = | |||
* [[Antithrombin|Antithrombin III]] | |||
* [[Defibrotide]] | |||
* [[Protein C]] | |||
** [[Drotrecogin alfa]]<sup>‡</sup> | |||
* [[Ramatroban]] | |||
* [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] | |||
}} | |||
| group3 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s | |||
| list3 = | |||
* [[Plasminogen activator]]s: [[Recombinant tissue plasminogen activators|r-tPA]] | |||
** [[Alteplase]] | |||
** [[Reteplase]] | |||
** [[Tenecteplase]] | |||
** [[Desmoteplase]]<sup>†</sup> | |||
* UPA | |||
** [[Saruplase]] | |||
** [[Urokinase]] | |||
* [[Anistreplase]] | |||
* [[Monteplase]] | |||
* [[Streptokinase]]<sup>#</sup> | |||
* Other [[serine endopeptidase]]s: [[Ancrod]] | |||
* [[Brinase]] | |||
* [[Fibrinolysin]] | |||
| group4 = [[Anticoagulant|Non-medicinal]] | |||
| list4 = | |||
* [[Citrate]] | |||
* [[Ethylenediaminetetraacetic acid|EDTA]] | |||
* [[Oxalate]] | |||
| | |||
| | |||
| belowstyle = background: transparent; padding: 0px; | |||
| below = {{PharmNavFootnote}} | |||
}}<noinclude> | }}<noinclude> | ||
{{collapsible option}} | |||
[[Category:Drug templates | [[Category:Drug templates by ATC]] | ||
</noinclude> | </noinclude> |
Revision as of 20:29, 9 February 2018
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state=
parameter may be used:
|state=collapsed
:{{Antithrombotics|state=collapsed}}
to show the template collapsed, i.e., hidden apart from its title bar|state=expanded
:{{Antithrombotics|state=expanded}}
to show the template expanded, i.e., fully visible|state=autocollapse
:{{Antithrombotics|state=autocollapse}}
If the |state=
parameter in the template on this page is not set, the template's initial visibility is taken from the |default=
parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse
.Template:Pp-template